Bellevue Life Sciences Acquisition Corp.
NASDAQ Capital MarketTotal Valuation
Bellevue Life Sciences Acquisition Corp. carries a market capitalization of 6.98M, placing it among publicly traded companies globally.
| Market Cap | 6.98M |
| Enterprise Value | N/A |
Share Statistics
Bellevue Life Sciences Acquisition Corp. currently has 4.04M shares outstanding.
| Shares Outstanding | 4.04M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Bellevue Life Sciences Acquisition Corp. trades at a trailing price-to-earnings ratio of 423.14.
| PE Ratio | 423.14 |
| PS Ratio | N/A |
| PB Ratio | 3.56 |
| P/TBV Ratio | 3.56 |
| P/FCF Ratio | -26.99 |
| P/OCF Ratio | -26.99 |
Financial Position
Bellevue Life Sciences Acquisition Corp. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.01 |
| Quick Ratio | 0.00 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -1.13 |
| Return on Assets (ROA) | -1.02 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Bellevue Life Sciences Acquisition Corp. has paid 376,802.00 in income taxes, reflecting an effective tax rate of 530.01.
| Income Tax | 376,802.00 |
| Effective Tax Rate | 530.01 |
Stock Price Statistics
Bellevue Life Sciences Acquisition Corp.'s stock has declined approximately -71.73709% over the past 52 weeks. The 50-day moving average sits at 10.74, while the 200-day moving average is 10.87.
| Beta (5Y) | N/A |
| 52-Week Price Change | -71.73709% |
| 50-Day Moving Average | 10.74 |
| 200-Day Moving Average | 10.87 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -2.24M, while operating income came in at -2.24M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.24M |
| Pretax Income | -98,056.00 |
| Net Income | -474,858.00 |
| EBITDA | -2.24M |
| EBIT | -2.24M |
| Earnings Per Share (EPS) | -0.10 |
Balance Sheet
Total book value stands at 14.91M, with working capital of -3.90M providing operational flexibility.
| Cash & Cash Equivalents | 12,236.00 |
| Total Debt | N/A |
| Net Debt | 1.77M |
| Equity (Book Value) | 14.91M |
| Book Value Per Share | 3.06 |
| Working Capital | -3.90M |
Cash Flow
Bellevue Life Sciences Acquisition Corp. produced -1.96M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.96M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.96M |
| FCF Per Share | -0.40 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 96.91 |
| FCF Yield | -3.70 |
Scores
Bellevue Life Sciences Acquisition Corp. posts an Altman Z-Score of 4.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.33 |